Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

American Journal of Physiology - Endocrinology and Metabolism

Volumn 310, Issue 11, 2016, Pages E947-E957

  Wei, Rui ^a   Ma, Shifeng ^a   Wang, Chen ^a   Ke, Jing ^a   Yang, Jin ^a   Li, Weihong ^a   Liu, Ye ^a   Hou, Wenfang ^a   Feng, Xinheng ^a   Wang, Guang ^a   Hong, Tianpei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

AMP activated protein kinase; Coronary flow velocity reserve; Endothelial nitric oxide synthase; Exenatide; Glucagon like peptide 1; Human umbilical vein endothelial cells; Type 2 diabetes mellitus

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; MULTIENZYME COMPLEX; ONCOPROTEIN; PEPTIDE; VENOM;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CELL FUNCTION; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY FLOW RESERVE; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE INCREASE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXERCISE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESTYLE; LIFESTYLE MODIFICATION; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN CONTENT; TREATMENT RESPONSE; UPREGULATION; WAIST CIRCUMFERENCE; BLOOD; CLINICAL TRIAL; DIABETIC ANGIOPATHIES; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG EFFECTS; ECHOCARDIOGRAPHY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ADULT; AMP-ACTIVATED PROTEIN KINASES; CARDIOTONIC AGENTS; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; NITRIC OXIDE SYNTHASE TYPE III; ONCOGENE PROTEIN V-AKT; PEPTIDES; SIGNAL TRANSDUCTION; VENOMS;

EID: 84983642507     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00400.2015     Document Type: Article

References (41)

1. Advani A, Bugyei-Twum A, Connelly KA. Cardiovascular effects of incretins in diabetes. Can J Diabetes 37: 309–314, 2013.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553, 1998.
3. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, Channon KM. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 112: 725–735, 2003.
4. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 35, Suppl 1: S11–S63, 2012.
5. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124: 335–345, 2011.
6. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59: 1030–1037, 2010.
7. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117: 2340–2350, 2008.
8. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293: E1289–E1295, 2007.
9. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436–447, 2006.
10. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, Heales S, Channon KM. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res 55: 838–849, 2002.
11. Cai S, Khoo J, Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res 65: 823–831, 2005.
12. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36: 2346–2350, 2013.
13. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagonlike peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61: 888–896, 2012.
14. Erdogdu O, Eriksson L, Xu H, Sjoholm A, Zhang Q, Nystrom T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 50: 229–241, 2013.
15. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKAand PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325: 26–35, 2010.
16. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE –/– mouse model. Diab Vasc Dis Res 8: 117–124, 2011.
17. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656–1662, 2002.
18. He L, Zeng H, Li F, Feng J, Liu S, Liu J, Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 299: E1061–E1065, 2010.
19. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43: 1435–1438, 2000.
20. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14–E22, 2001.
21. Hozumi T, Yoshida K, Akasaka T, Asami Y, Ogata Y, Takagi T, Kaji S, Kawamoto T, Ueda Y, Morioka S. Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol 32: 1251–1259, 1998.
22. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 10: 72–77, 2013.
23. Koska J. Incretins and preservation of endothelial function. Cardiovasc Hematol Agents Med Chem 10: 295–308, 2012.
24. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 9: e97554, 2014.
25. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagonlike peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201: 59–66, 2009.
26. Liu J, Lu C, Li F, Wang H, He L, Hao Y, Chen AF, An H, Wang X, Hong T, Wang G. PPARα Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level Through Increasing the Expression of Guanosine 5′- Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells. PPAR Res 2011: 523520, 2011.
27. Liu J, Wang Y, An H, Liu J, Wei J, Wang H, Wang G. Correlation between arterial stiffness and coronary flow velocity reserve in subjects with pulse wave velocity >1400 cm/s. Clin Exp Hypertens 38: 89–94, 2016.
28. Meimoun P, Tribouilloy C. Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world. Eur J Echocardiogr 9: 449–457, 2008.
29. Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res 11: 419–430, 2014.
30. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209–E1215, 2004.
31. Oyama J, Higashi Y, Node K. Do incretins improve endothelial function? Cardiovasc Diabetol 13: 21, 2014.
32. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8: 419–428, 2006.
33. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126, 1999.
34. Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36: 1532–1541, 2004.
35. Wang G, He L, Liu J, Yu J, Feng X, Li F, Hao Y, Mao J, Hong T, Chen AF, Wang X. Coronary flow velocity reserve is improved by PPAR-alpha agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther 31: 161–167, 2013.
36. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 58: 1893–1901, 2009.
37. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, Zou MH. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 52: 484–490, 2008.
38. Yoshino Y, Ishisaka M, Tsujii S, Shimazawa M, Hara H. Glucagonlike peptide-1 protects the murine hippocampus against stressors via Akt and ERK1/2 signaling. Biochem Biophys Res Commun 458: 274–279, 2015.
39. Yu J, Han JL, He LY, Feng XH, Li WH, Mao JM, Gao W, Wang G. Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes. J Geriatr Cardiol 10: 159–164, 2013.
40. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, Mao J, Wang G, Wang X. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 38: 86–94, 2010.
41. Zhou SJ, Bai L, Lv L, Chen R, Li CJ, Liu XY, Yu DM, Yu P. Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway. Mol Med Rep 10: 2587–2594, 2014.